Activation of cytosolic phospholipase A2 in human T-lymphocytes involves inhibitor-κB and mitogen-activated protein kinases

European Journal of Pharmacology

Volumn 466, Issue 1-2, 2003, Pages 169-180

  Burgermeister, Elke ^a   Endl, Josef ^b   Scheuer, Werner V ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Interleukin 2; MAP (mitogen activated protein) kinase; NF B (nuclear factor B); Phospholipase A2; T lymphocyte

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ANTIGEN; ARACHIDONIC ACID DERIVATIVE; CALCIMYCIN; CIGLITAZONE; CYCLOSPORIN A; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; LECTIN; LEUKOTRIENE B4; LINOLEIC ACID; LINOLENIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENYLACETIC ACID; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHOLIPASE A2; PROSTAGLANDIN A2; PYRROLIDINE DITHIOCARBAMATE;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSACTIVATION;

EID: 0037432644     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01492-4     Document Type: Article

References (51)

1. Alexander L.D., Cui X.L., Falck J.R., Douglas J.G. Arachidonic acid directly activates members of the MAPK superfamily in rabbit proximal tubule cells. Kidney Int. 59:2001;2039-2053.
2. 2. Eur. J. Pharmacol. 326:1997;237-250.
3. 2s regulating NFκB activation in response to tumor necrosis factor-alpha and interleukin-1 beta. J. Biol. Chem. 276:2001;35344-35351.
4. 2 in remodeling and increased susceptibility of proliferating T-cells to CoA-independent transacyclase inhibitor-induced apoptosis. J. Biol. Chem. 276:2001;17568-17575.
5. Brash A.R. Arachidonic acid as a bioactive molecule. J. Clin. Invest. 107:2001;1339-1345.
6. Breyer R.M., Bagdassarian C.K., Myers S.A., Breyer M.D. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 41:2001;661-690.
7. 2. Eur. J. Pharmacol. 369:1999;373-386.
8. 2 attenuates activation of MAPK in human monocytic cells. Eur. J. Pharmacol. 388:2000;195-208.
9. 2, mediators of inflammation, proliferation and apoptosis. Prog. Lipid Res. 40:2000;167-197.
10. Chang L.C., Wang J.P. Signal transduction pathways for activation of ERK by arachidonic acid in rat neutrophils. J. Leukoc. Biol. 69:2001;659-665.
11. Cifone M.G., Cironi L., Santoni A., Testi R. Diacylglycerol lipase activation and 5-lipoxygenase activation and translocation following T-cell receptor/CD3 triggering in T-cells. Eur. J. Immunol. 25:1995;1080-1086.
12. Clark R.B. The role of PPARs in inflammation and immunity. J. Leukoc. Biol. 71:2002;388-400.
13. 2 activation and arachidonic acid release. Biochem. Soc. Trans. 21:1993;496S.
14. Cunningham F.M. Lipid Mediators, The Handbook of Immunopharmacology. 2nd ed. 1994;Academic Press, London.
15. Dong C., Davis R.J., Flavell R.A. MAPK in the immune response. Annu. Rev. Immunol. 20:2002;55-72.
16. Dumont F.J., Staruch M.J., Fischer P., DaSilva C., Camacho R. Inhibition of T-cell activation by pharmacological disruption of the MEK1/ERK MAPK or calcineurin signaling pathways results in differential modulation of cytokine production. J. Immunol. 160:1998;2579-2589.
17. Endl J., Otto H., Jung G., Dreisbusch B., Donie F., Stahl P., Elbracht R., Schmitz G., Meinl E., Hummel M., Ziegler A.G., Wank R., Schendel D.J. Identification of naturally processed T-cell epitopes from glutamic acid decarboxylase presented in the context of HLA-DR alleles by T-lymphocytes of recent onset insulin-dependent diabetes mellitus patients. J. Clin. Invest. 99:1997;2405-2415.
18. 2, 5-lipoxygenase and prostaglandin H synthase-2 in acute pre-B-lymphocytic leukaemia cells. Br. J. Haematol. 90:1995;585-594.
19. Garofalo T., Sorice M., Misasi R., Cinque B., Giammatteo M., Pontieri G.M., Cifone M.G., Pavan A. A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. Involvement of serine phosphorylation and protein kinase C delta translocation. J. Biol. Chem. 273:1998;35153-35160.
20. 2 correlate with lymphocyte maturation. J. Immunol. 156:1996;2054-2061.
21. Gilmour R.S., Mitchell M.D. Nuclear lipid signaling: novel role of eicosanoids. Exp. Biol. Med. 226:2001;1-4.
22. Hii C.S.T., Huang Z.H., Bilney A., Costabile M., Murray A.W., Rathjen D.A., Channing J.D., Ferrante A. Stimulation of p38 phosphorylation and activity by arachidonic acid in HeLa cells, HL60 promyelocytic leukemic cells and human neutrophils. J. Biol. Chem. 273:1998;19277-19282.
23. Huang H.C., Huang Y.L., Chang J.H., Chen C.C., Lee Y.T. Possible mechanism of immunosuppressive effect of scoparone (6,7-dimethoxycoumarin). Eur. J. Pharmacol. 217:1992;143-148.
24. 2. Biochem. 35:1996;3712-3721.
25. Jiao H., Cui X.L., Torti M., Chang C.H., Alexander L.D., Lapetina Douglas J.G. Arachidonic acid mediates angiotensin II effects on p21ras in renal proximal tubular cells via the tyrosine kinase-Shc-Grb2-Sos pathway. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7417-7421.
26. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature. 405:2000;421-424.
27. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., Han K., DiGregorio G.B., Katzenellenbogen J.A., Katzenellenbogen B.S., Roberson P.K., Weinstein R.S., Jilka R.L., Manolagas S.C. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 104:2001;719-730.
28. 2 activity beside the phospholipase C pathway in human T-lymphocytes. J. Immunol. 144:1990;2359-2364.
29. Li W., Whaley C.D., Mondino A., Mueller D.L. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T-cells. Science. 271:1996;1272-1276.
30. 2 by methyl arachidonyl fluorophosphonate. Biochim. Biophys. Acta. 1302:1996;55-60.
31. Los M., Schenk H., Hexel K., Baeuerle P.A., Dröge W., Schulze-Osthoff K. Interleukin-2 gene expression and NFκB activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J. 14:1995;3731-3740.
32. 2. Antisense Nucleic Acid Drug Dev. 8:1998;153-157.
33. Migliaccio A., Piccolo D., Castoria G., Di Domenico M., Bilancio A., Lombardi M., Gong W., Beato M., Auricchio F. Activation of the Src/p21ras/ERK pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17:1998;2008-2018.
34. Mihm S., Ennen J., Pessara U., Kurth R., Dröge W. Inhibition of human immunodeficiency virus-1 replication and NFκB activation by cysteine and cysteine derivatives. AIDS. 5:1991;497-503.
35. 2. Crit. Rev. Immunol. 17:1997;225-283.
36. Paine E., Palmantier R., Akiyama S.K., Olden K., Roberts J.D. Arachidonic acid activates MAPK-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAPK-dependent pathway. J. Biol. Chem. 275:2000;11284-11290.
37. Razandi M., Oh P., Pedram A., Schnitzer J., Levin E.R. Estrogen receptors associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol. Endocrinol. 16:2002;100-115.
38. Reddy M.A., Thimmalapura P.R., Lanting L., Nadler J.L., Fatima S., Natarajan R. The oxidized lipid and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cycloAMP response element-binding protein activation. Mediation of angiotensin II effects. J. Biol. Chem. 277:2002;9920-9928.
39. Rosen E.D., Spiegelman B.M. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276:2001;37731-37734.
40. 2 mediates lymphocyte proliferation. J. Biol. Chem. 275:2000;35692-35698.
41. 2 as defined by gene knockouts. Biochim. Biophys. Acta. 1488:2000;139-148.
42. Song R.X., McPherson R.A., Adam L., Bao Y., Shupnik M., Kumar R., Santen R.J. Linkage of rapid estrogen action to MAPK activation by estrogen receptor alpha-Shc association and Shc pathway activation. Mol. Endocrinol. 16:2002;116-127.
43. Straus D.S., Glass C.K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21:2001;185-210.
44. 2. Biochem. 32:1993;5935-5940.
45. 2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J. Biol. Chem. 276:2001;48950-48955.
46. Tilley S.L., Coffman T.M., Koller B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 108:2001;15-23.
47. 2-induced stimulation of MAPK (ERK and JNK). Eur. J. Biochem. 244:1997;587-595.
48. 2. Biochem. 32:1993;12560-12565.
49. Werlen G., Palmer E. The T-cell receptor signalosome: a dynamic structure with expanding complexity. Curr. Opin. Immunol. 14:2002;299-305.
50. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., Farrar W.L. Activation of human T-lymphocytes is inhibited by PPARγ agonists. PPARγ co-association with transcription factor NFAT. J. Biol. Chem. 275:2000;4541-4544.
51. 2-linked cascade in signaling by an oncogenic, constitutively active Ha-Ras isoform. J. Biol. Chem. 276:2001;24645-24653.